Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: A multicenter clinical trial

Journal of the National Cancer Institute

Volumn 84, Issue 5, 1992, Pages 328-332

  Tangrea, Joseph A ^a,b   Edwards, Brenda K ^a,b   Taylor, Philip R ^a,b   Hartman, Anne M ^a,b   Peck, Gary L ^a,b   Salasche, Stuart J ^a,c   Menon, Padman A ^a,d   Benson, Paul M ^a,e   Mellette, J Ramsey ^a,f   Guill, Marshall A ^a,g   Robinson, June K ^a,h   Guin, Jere D ^a,i   Stoll, Howard L ^j   Grabski, William J ^a,c   Winton, George B ^a,e  

^a Isotretinoin Basal Cell Carcinoma Study Group ^*  (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f Fitszimons Army Medical Center   (United States)

^g EISENHOWER ARMY MEDICAL CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^j ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; CANCER PREVENTION; CANCER RECURRENCE; CONTROLLED STUDY; DOSE RESPONSE; DRY SKIN; FEMALE; HUMAN; HYPEROSTOSIS; HYPERTRIGLYCERIDEMIA; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MUCOSA; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; XEROSIS;

AGED; ANTICARCINOGENIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; HUMAN; ISOTRETINOIN; MALE; MIDDLE AGE; SKIN NEOPLASMS;

EID: 0026520405     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.5.328     Document Type: Article

References (35)

1. Bogovski P: Tumours of the skin. IARC Sci Publ 23:1-41, 1979
2. Pinkus H: Factors involved in skin carcinogenesis. J Am Acad Dermatol 1:267-275, 1979
3. American Cancer Society: Cancer Facts and Figures. Publ No. 90-425M. No. 5008-LE. Washington, DC: ACS, 1990
4. Scotto J, Fears TR, Fraumeni JF Jr: Incidence of nonmelanoma skin cancer in the United States. DHEW Publ No. (NCI) 82-2433. Washington, DC: US Govt Print Off. 1983
5. Bergstresser PR, Halprin KM: Multiple sequential skin cancers. The risk of skin cancer in patients with previous skin cancer. Arch Dermatol 111:995-996, 1975
6. Epstein E: Value of follow-up after treatment of basal cell carcinoma. Arch Dermatol 108:798-800, 1973
7. Robinson JK: Risk of developing another basal cell carcinoma: A 5-year prospective study. Cancer 60:118-120, 1987
8. Peck GL, Yoder FW, Olsen TG, et al: Treatment of Darier's disease, lamellar ichthyosis, pityriasis rubra pilaris, cystic acne, and basal cell carcinoma with oral 13-cis-retinoic acid. Dermatologica 157:11-12, 1978
9. Peck GL, Gross EG, Butkus D, et al: Chemoprevention of basal cell carcinoma with isotretinoin. J Am Acad Dermatol 6:815-823, 1982
10. Jones DH, King K, Miller AJ, et al: A dose-response study of 13-cis-retinoic acid in acne vulgaris. Br J Dermatol 108:333-343, 1983
11. Tangrea J, Edwards B, Hartman A, et al: Isotretinoin-basal cell carcinoma prevention trial. Design, recruitment results, and baseline characteristics of the trial participants. Controlled Clin Trials 11:433-450, 1990
12. Tangrea J A, Adrianza ME, McAdams M: A method for the detection and management of adverse events in clinical trials. Drug Inform J 25:63-80, 1991
13. Kilcoyne RF, Cope R, Cunningham W, et al: Minimal spinal hyperostosis with low-dose isotretinoin therapy. Invest Radiol 21:41-44, 1986
14. Kilcoyne RF: Acitretin effects on the spine. In Retinoids, 10 Years On. Proceedings of the symposium held at Geneva, November 18, 1990 (Saurat JH, ed). Basel: S. Karger. In press
15. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
16. Miller RG Jr: Survival Analysis. New York: John Wiley & Sons, 1981
17. Freedman L, Sylvester R, Byar DP: Using permutation tests and bootstrap confidence limits to analyze repeated events data from clinical trials. Controlled Clin Trials 10:129-141, 1989
18. Snedecor GW, Cochran WG: Statistical Methods, 6th ed. Ames, Iowa: Iowa State Univ Press, 1967
19. Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research, Principles, and Quantitative Methods. London: Wadsworth, 1982
20. FiTZPATRicK TB, Eisen AZ, Wolff K, et al: Dermatology in General Medicine, 3rd ed. New York: McGraw-Hill, 1987
21. Kraemer KH, DiGiovanna JJ, Moshell AN, et al: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318:1633-1637, 1988
22. Peck GL, DiGiovanna JJ, Sarnoff DS, et al: Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 19:176-185, 1988
23. Peck GL: Long-term therapy is needed for maintenance of cancer chemopreventive effect. Dermatologica 175:138-144, 1987
24. Goldberg LH, Hsu SH, Alcalay J: Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol 21:144-145, 1989
25. Pittsley RA, Yoder FW: Retinoid hyperostoses. Skeletal toxicity associated with long term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med 308:1012-1014, 1983
26. Pennes DR, Ellis CN, Madison KC, et al: Early skeletal hyperostoses secondary to 13-cis-retinoic acid. AJR Am J Roentgenol 142:979-983, 1984
27. McGuire J, Milstone L, Lawson J: Isotretinoin administration alters juvenile and adult bone. In Retinoids: New Trends in Research and Therapy (Saurat JH, ed). Basel: S. Karger, 1985, pp 419-439
28. Carey BM, Parkin GJ, Cunliffe WJ, et al: Skeletal toxicity with isotretinoin therapy: A clinico-radiological evaluation. Br J Dermatol 119:609-614, 1988
29. Pennes DR, Martel W, Ellis CN, et al: Evolution of skeletal hyperostoses caused by 13-cis-retinoic acid therapy. AJR Am J Roentgenol 151:967-973, 1988
30. Kilcoyne RF: Effects of retinoids in bone. J Am Acad Dermatol 19:212-216, 1988
31. Archer CB, Elias PM, Lowe NJ, et al: Extensive spinal hyperostosis in a patient receiving isotretinoin: Progression after 4 years of etretinate therapy. Clin Exp Dermatol 14:319-321, 1989
32. White SI, Mackie RM: Bone changes associated with oral retinoid therapy. Pharmacol Ther 40:137-144, 1989
33. Resnick D, Niwayama G: Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology 119:559-568, 1976
34. Schlapbach P, Beyeler C, Gerber NJ, et al: Diffuse idiopathic hyperostosis (DISH) of the spine: A cause of back pain? A controlled study. Br J Rheumatol 28:299-303, 1989
35. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990